



Late-Breaking Clinical Trial (LBCT) Submission Instructions

Thank you for your interest in submitting an LBCT to ACC.27-WCC. Please read the following instructions carefully.

Section 1 walks you through the submission process on the portal.

Section 2 contains important information for you once your submission is complete.

SECTION 1: SUBMITTING YOUR LBCT ON THE ACC PORTAL

You can begin your LBCT submission by visiting the ACC.27-WCC site and clicking on the “Submit Your Science” button at the top of the page.

To submit an LBCT, you must have an ACC account. If you do not have an ACC account, you can create one for free using the “Create Free Account” link after you click the “Submit Your Science” button.

Tab 1: Title

- **Do NOT:**
 - Bold, italicize, underline, superscript or subscript any items in the title.
 - Include authors or institutions in the title. If you do, they will be removed.
 - Use the “Enter” button in your title. This action will add hard returns, which are not allowed.
 - Use abbreviations unless they are commonly known.
 - End the title with a period.
 - Use a comma before “and” in a series.
 - Use quotation marks in a title.
- **DO:**
 - Use a comma for numbers 1,000 and above.
 - Substitute a colon for a dash/hyphen except when using prefixes.
 - Hyphenate the first prefix word when there is more than one prefix word used such as Non- Anti...

Tab 2: Category

Submit your LBCT to one of the following categories, based on its area of research. LBCTs submitted to a category that do not match the subject matter of the abstract may be given a low score from reviewers.

- Cardiac Arrhythmias
- Cardiovascular Disease Prevention
- Congenital Heart Disease
- Coronary, Peripheral and Structural Interventions
- Heart Failure and Cardiomyopathies
- Ischemic Heart Diseases
- Multimodal Imaging
- Pulmonary Vascular Disease
- Valvular Diseases
- Vascular Diseases



Tab 3: Trial Description

Please complete all required fields on this tab. The information collected in this section will be used by ACC.27-WCC planners and reviewers to evaluate your submission and determine its appropriateness for presentation.

Trial Type

- Select the **one trial type** that best describes your submission. Choosing the most appropriate category will help ensure your study is reviewed by the appropriate experts.
 - **Phase 2 or Phase 3 Multicenter Randomized Controlled Trial:** Results from multicenter Phase 2 or Phase 3 randomized trials.
 - **Single-Center Randomized Controlled Trial or Phase 1 Multicenter Randomized Controlled Trial:** Results from single-center randomized Phase 2 or Phase 3 controlled trials or multicenter Phase 1 trials.
 - **Technology Advances or Novel Human Therapeutics:** Studies evaluating new technologies, devices, diagnostics, digital health innovations, or novel therapeutic approaches in human subjects.
 - **Multicenter Observational Study or Registry:** Studies based on data collected from multiple centers without intervention, including registries, cohorts, and epidemiologic studies.
 - **Secondary Analysis of Major Clinical Trial:** New analyses derived from previously completed major clinical trials, including subgroup analyses, long-term follow-up, or secondary endpoints.

Enrollment

- Provide information regarding patient enrollment:
 - Total number of patients enrolled in the study.
 - Enrollment start date.
 - Indicate whether enrollment has been completed.
 - If enrollment is ongoing, provide the anticipated completion date.

Analysis

- Indicate whether analysis of the study data has been completed.
- If the analysis is not yet complete, provide the anticipated completion date.

Responsibility

- Provide contact information for the individual and organization responsible for coordinating the study:
 - Responsible Individual at Data Coordinating Center
 - Data Coordinating Center(s)
 - Institution

Findings

- Responses to each question in this section are limited to **250 characters**.
 - **If you were summarizing your research in a few sentences, what would you emphasize?**
 - Provide a concise overview of the study's purpose, design, and significance.
 - **If your analysis is complete, what is the most important finding?**
 - Describe the primary result, outcome, or conclusion that makes this study impactful.

Published Name of Trial

- If applicable, provide:
 - Published acronym



- Published name of trial
- Journal citation
- Clinicaltrials.gov NCT Number

Industry Sponsor

- If applicable, provide the full name of the sponsoring company.

Tab 4: Abstract Text

Body/Text:

- Abstracts must meet size limits to be reviewed. Incomplete submissions will not be considered.
- Limit: **1,900 characters (excluding spaces)**. Each graphic, table, or image counts as **600 characters** toward this limit.
- Type your abstract directly into the text boxes provided. Upload graphics/images separately. If you are pasting text, paste as **plain text** only.
- **Do not** insert hard returns at the end of lines.
- You may use up to **five (5) unique abbreviations**. Spell out the term with the abbreviation in parentheses on first use.
- **Do not** include the title, authors, or institution in the abstract body. These are entered separately.
- Use the following structure with headings:
 - **Background:** One to two sentences on the purpose of the study.
 - **Methods:** Briefly describe the methods used.
 - **Results:** Key findings with enough detail to support conclusions.
 - **Conclusion:** State conclusions reached. Avoid vague phrases like “results will be discussed.”
- **Proofread carefully. Please proofread carefully for factual, spelling, and size errors.**

Adding An Image to Your Submission:

- On the **Abstract** tab, you can upload a picture, table and/or graph.
- Accepted file type: .jpeg only. Other formats may be uploaded but will not be reviewed or published.
- **Each image counts as 600 characters and is included as part of the 1,900-character limit.**
- Avoid large or complex graphics, as they may not display clearly.

Tab 5: Author Information

To add an author, please click Add an Author:

- List the complete name including a full first name and initials.
- Multiple word first names should be placed in the “First Name” field.
- Use English characters when entering names.
- Do not:
 - Include title, degrees, or suffix in the “Last Name” field.
 - Enter more than one author in each “First Name” or “Last Name” field.
 - Use any non-English characters such as tildes and umlauts.
- If more than one LBCT is submitted, spell each author’s name exactly the same. This is important when indexing all authors in the online/mobile program planner systems.
- The author order is the order in which authors will be listed in publications if the abstract is selected for presentation. The person who is expected to be the presenter does not need to appear as the first author.
- The contact information is not used as part of the institutions listed in any LBCT publication. Institutions are entered separately.



- You may change who is presenting by clicking **Change who is Presenting** when there is more than one author listed.
- The submitting author will be notified about the outcome of the review and selection process.

You may also add an author group by clicking **Add a Group**:

- Use the Author Group field only for the name of an investigative team or study group, such as “Investigators for ACC.” Do not use this field to list individual authors.
- If individual authors are entered in the Author Group field, you will be contacted to correct the submission.
- Authors listed only as part of an Author Group will not be included in the author index of onsite program materials.

Tab 6: Lead Investigator

- Select a Lead Investigator from the list provided.
- The Lead Investigator must have a current disclosure on file.

Tab 7: Payment

- A non-refundable \$399 USD processing fee is required per LBCT submission, payable online by credit card only.
- Purchase orders, checks, and bank transfers are not accepted.
- Your card will be charged when you click **Save and Continue**.
- Click this button **only once** to avoid duplicate charges.
- If a presenter’s submission is accepted into a LBCT session, the registration fee for ACC.27-WCC is waived.

Tab 8: Review and Submission Completion

- A submission is complete when the **Review My Work** tab displays: “This submission is complete and will be sent to review.”
- Submissions are sent to reviewers after the deadline. You may edit your abstract until **1 p.m. ET on Tuesday, Dec. 1, 2026**.
- The last edited date/time appears in the **Review My Work** tab and updates with each change.
- From the **Review My Work** page, you can also send yourself a confirmation email and print a final version of your submission.

SECTION 2: IMPORTANT INFORMATION AFTER YOUR SUBMISSION IS COMPLETE

Revising Your Submission

- You may revise your abstract until **1 p.m. ET on Tuesday, Dec. 1, 2026**.
- No changes will be accepted after the deadline—including edits to the text, authors, or uploaded files.
- After making changes, go to the **Review My Work** tab to confirm completion.
- Ensure it displays: **“This submission is complete and will be sent to review.”**

Notification of Acceptance

- The presenting author will be emailed a notification with the status of the submission on **Tuesday, Feb. 20, 2027**.
- Authors can also check the status of their submissions by returning to the submission portal.



Changing Presenting Authors

- If your LBCT is accepted, you may change the presenting author to anyone listed in your author block.
- You cannot add new authors or assign a presenting author who is not already listed.
- If the LBCT is selected for presentation, the presenting author may be changed by emailing Matthew Parks (mparks@acc.org).
- Presenting author changes can be made up until the start of ACC.27-WCC.

Withdrawals

- To withdraw an LBCT submission, send written notice to Matthew Parks (mparks@acc.org). Be sure to include the LBCT title and control number. *Tip: Use the summary page to assist with this.*
- If your LBCT is accepted, you must withdraw any other type of submission that is accepted or submitted to ACC.27-WCC (e.g., abstract) that contains, in whole or in part, data that are included in the LBCT submission. Failure to comply with the ACC's embargo policy set forth in the [ACC.27-WCC Media Communications Policies](#) may result in a broken embargo and subject the LBCT and presenters to penalties, including removal from the ACC.27-WCC LBCT program.